GlassScriptPhysician profile
Edward Detweiler
NPI 1588152789
$2,206.54
in general payments reported to CMS, 2019-2025
22 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.39 · 2022: $43.94 · 2023: $768 · 2024: $901 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $397.61 | 2023-2025 | |
| Novo Nordisk INC | $217.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $190.48 | 2023-2025 | Mounjaro, Zepbound |
| Teleflex LLC | $173.49 | 2023 | Urolift |
| Astrazeneca Pharmaceuticals LP | $161.68 | 2022-2024 | Airsupra, Farxiga |
| Abbvie INC. | $139.04 | 2024-2025 | |
| Exact Sciences Corporation | $111.87 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $97.71 | 2023-2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $91.45 | 2023-2024 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $85.84 | 2023-2025 | |
| Myriad Women'S Health, INC. | $66.86 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $61.58 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Kiniksa Pharmaceuticals International, Plc | $58.47 | 2024 | Arcalyst |
| Amgen INC. | $53.95 | 2025 | Otezla, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.85 | 2023-2024 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $45.58 | 2023 | Arcalyst |
| Orthofix Medical, INC. | $40.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.11 | 2024-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $27.04 | 2022 | |
| Axsome Therapeutics, INC. | $26.96 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $14.61 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Detweiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.